Results 281 to 290 of about 17,219,459 (310)

Peptide-based PET tracer targeting LAG-3 for evaluating the efficacy of immunotherapy in melanoma. [PDF]

J Immunother Cancer
Yuan P, Long Y, Wei N, Wang Y, Zhu Z, Han J, Jiang D, Lan X, Gai Y.   +8 more
europepmc   +1 more source

Correction to "Upregulation of HLA-II Related to LAG-3⁺CD4⁺ T Cell Infiltration is Associated With Patient Outcome in Human Glioblastoma". [PDF]

Cancer Sci
europepmc   +1 more source

Author Correction: Resistance to anti-LAG-3 plus anti-PD-1 therapy in head and neck cancer is mediated by Sox9+ tumor cells interaction with Fpr1+ neutrophils. [PDF]

Nat Commun
Wang X, Cheng M, Chen S, Zhang C, Ling R, Qiu S, Chen K, Zhou B, Li Q, Lei W, Chen D.   +10 more
europepmc   +1 more source

Plasma levels of soluble PD-1, TIM-3, LAG-3 and galectin-3 and the degree of liver fibrosis in CHC and the impact of successful antiviral treatment on their levels. [PDF]

Sci Rep
Osuch S, Kumorek A, Kozłowski P, Berak H, Kochanowicz AM, Cortés-Fendorf K.   +5 more
europepmc   +1 more source

From Virtual Screens to Cellular Target Engagement: New Small Molecule Ligands for the Immune Checkpoint LAG-3. [PDF]

ACS Med Chem Lett
Fuchs N, Calvo-Barreiro L, Talagayev V, Pach S, Wolber G, Gabr MT.   +5 more
europepmc   +1 more source

Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study. [PDF]

J Hematol Oncol
Mao C, Xiong A, Qian J, Wang W, Liu Y, Zhang T, Wu Z, Ni H, Lu J, Long S, Zhao L, Chen Y, Zhou C, Xu N.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Interferon Biology and LAG-3 Shedding in PD-(L)1 plus LAG-3 Immunotherapy

Clinical Cancer Research, 2022
Summary Targeting coinhibitory receptors on dysfunctional T cells may improve response to anti–PD-(L)1 in the IFNγ associated T-cell–inflamed tumor microenvironment. The bispecific lymphocyte activation gene 3 (LAG-3) and PD-L1 blocking antibody FS118, potentially through LAG-3 shedding, represents a promising strategy to improve ...
Lilit Karapetyan, Jason J. Luke
openaire   +2 more sources

Advancement of anti‐LAG‐3 in cancer therapy

The FASEB Journal, 2023
Immune checkpoint inhibitors have effectively transformed the treatment of many cancers, particularly those highly devastating malignancies. With their widespread popularity, the drawbacks of immune checkpoint inhibitors are also recognized, such as drug
Yunong Li, Mingyi Ju, Yuxi Miao, Lin Zhao, Lijuan Xing, Minjie Wei   +5 more
semanticscholar   +1 more source

Simultaneous inhibition of PD-1 and LAG-3: the future of immunotherapy?

Immunotherapy, 2023
Immunotherapy has improved the prognosis of many cancers, yet a large number of patients have demonstrated resistance to current immune checkpoint inhibitors.
Sasha-Jane Abi-Aad, Joseph Zouein, Antoine Chartouni, Nabih Naim, H. Kourie   +4 more
semanticscholar   +1 more source

LAG-3: a very singular immune checkpoint

Nature Immunology, 2018
The mechanism of action of the lymphocyte checkpoint protein LAG-3 was always rather mysterious. It now seems to operate at least in part by recognizing and suppressing responses to stable complexes of peptide and major histocompatibility complex class II.
Lui, Y, Davis, S
openaire   +3 more sources